European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
…, F Cervantes, RE Clark, JE Cortes… - Blood, The Journal …, 2013 - ashpublications.org
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet …
inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet …
One-third of reef-building corals face elevated extinction risk from climate change and local impacts
…, S Banks, A Bruckner, A Chiriboga, J Cortes… - Science, 2008 - science.org
The conservation status of 845 zooxanthellate reef-building coral species was assessed by
using International Union for Conservation of Nature Red List Criteria. Of the 704 species …
using International Union for Conservation of Nature Red List Criteria. Of the 704 species …
[HTML][HTML] Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …
[HTML][HTML] Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer
Background Trastuzumab emtansine is the current standard treatment for patients with
human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose …
human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose …
[HTML][HTML] Event-free survival with pembrolizumab in early triple-negative breast cancer
Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …
significantly higher percentage of patients with early triple-negative breast cancer having a …
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
…, CE Bueso-Ramos, JE Cortes… - Blood, The Journal …, 2022 - ashpublications.org
The classification of myeloid neoplasms and acute leukemias was last updated in 2016
within a collaboration between the World Health Organization (WHO), the Society for …
within a collaboration between the World Health Organization (WHO), the Society for …
[HTML][HTML] Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
J Baselga, J Cortés, SB Kim, SA Im… - … England Journal of …, 2012 - Mass Medical Soc
Background The anti–human epidermal growth factor receptor 2 (HER2) humanized monoclonal
antibody trastuzumab improves the outcome in patients with HER2-positive metastatic …
antibody trastuzumab improves the outcome in patients with HER2-positive metastatic …
Discontinuous dynamical systems
J Cortes - IEEE Control systems magazine, 2008 - ieeexplore.ieee.org
This article has presented an introductory tutorial on discontinuous dynamical systems.
Various examples illustrate the pertinence of the continuity and Lipschitzness properties that …
Various examples illustrate the pertinence of the continuity and Lipschitzness properties that …
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer …
Background Pembrolizumab monotherapy showed durable antitumour activity and manageable
safety in patients with metastatic triple-negative breast cancer. We aimed to examine …
safety in patients with metastatic triple-negative breast cancer. We aimed to examine …
[HTML][HTML] Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
…, E Clark, G Ross, MC Benyunes, J Cortés - New England journal …, 2015 - Mass Medical Soc
Background In patients with metastatic breast cancer that is positive for human epidermal
growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-…
growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-…